Hong Kong-listed 3SBio made its second big move in as many months since it came back onto the market, buying small molecule maker Zhejiang Wansheng Pharma for $85 million.
India's Sun Pharmaceutical Industries has decided that a triage strategy is needed to address the poor state of four Ranbaxy Laboratories manufacturing plants banned by the U.S. FDA in the past 5 years. And that may mean one unit may not make it, the Economic Times reports.
Contract drug developer Avista Pharma Solutions bought the manufacturing, development and animal health services business of rival Scynexis, building up its capacity to take a larger share of an expanding market.
Repeated quality violations by Indian drug manufacturing and contract research firms are casting a long shadow on the country's hopes to be a key global supplier of medicines and services. And they come at a particularly acute time for Biocon, which opens an initial public offering for its Syngene unit next week.
A thwarted challenge from an activist investor to block the $8 billion merger of Samsung C&T and Cheil Industries last week has set the stage for family-controlled Samsung Electronics and related units to focus on boosting already rapid growth at Samsung BioLogics and Samsung Bioepis, the Korea Herald reports.
Sun Pharmaceutical Industries founder and managing director Dilip Shanghvi said earlier this year his first priority after the purchase of Ranbaxy Laboratories was to solve regulatory and integration issues. This week, he presented the bill to investors.
Hays Recruiting in Singapore says jobs in biopharma niches in manufacturing, regulatory and sales are up for grabs in the island nation, topping its latest quarterly regional outlook of skills in demand through September 2015, according to a press release.
Shanghai will build a China FDA medicine evaluation center to speed drug approvals, CNTV said on its website, as part of efforts to keep and attract drug and device firms to the region.
India's troubles with pharmaceutical manufacturing widened this week as the U.S. FDA issued an import alert for the Emcure Pharmaceuticals plant in Hinjawadi, citing deficiencies in good manufacturing practices at the site with no specifics immediately available.
Multinational biologic trials in Asia are a "big driver" behind U.K.-based Almac Group's launch of a Singapore-based Asian headquarters, but business from emerging biotechs would be icing on the cake, company executives told FiercePharmaAsia in an interview.